Osteogenesis imperfecta

Overview

Board takeaway: Plan gentle transfers, supported positioning, early protection of defective dentin, and medically coordinated extraction when needed.

A type I collagen defect causing fragile bones, blue sclerae and, in many patients, dentinogenesis imperfecta.

How does Osteogenesis imperfecta affect dental management?

• Early coverage: Stainless steel crowns on primary molars and full coverage early to prevent wear
• Handling: Plan careful transfers and supported positioning.
• Stabilization limit: Avoid forceful restraint or any immobilization that cannot be performed safely; AAPD identifies bone fragility as a stabilization risk, and inability to immobilize safely as a contraindication.
• Medication review: Review bisphosphonate/other antiresorptive treatment with the medical team.
• Infection and prognosis: Preserve a restorable tooth when prognosis supports it; drug exposure does not justify leaving infection untreated.
• Risk discussion: Discuss surgical healing and medication-related osteonecrosis risk without treating it as either zero or an automatic extraction ban.
• Extractions: handle brittle bone gently and support the jaw.
• Before GA: assess cervical spine abnormalities and ask about basilar invagination.
• Restoration: anterior teeth may need crowns or composite, with full coverage of permanent teeth later.

Loading diagram…

Assess whether a tooth can be predictably preserved. An infected nonrestorable tooth needs definitive care despite antiresorptive exposure; coordinate surgical risk, technique, and healing rather than inventing a drug holiday.

Exam pearl

What is Osteogenesis imperfecta?

A group of inherited connective-tissue disorders causing fragile bones and recurrent fractures, most commonly through defects in the quantity or structure of type I collagen.

What are the main systemic features of Osteogenesis imperfecta?

• Genetics: COL1A1 or COL1A2 mutation, mostly autosomal dominant; ~1 in 15,000–20,000 births
• Types: Type I (mildest, blue sclerae), II (lethal perinatal), III (progressive deforming), IV (moderate)
• Systemic features: Recurrent fractures, bowing, short stature, hearing loss, Wormian bones, basilar invagination
• Treatment: Treated with bisphosphonates (pamidronate, zoledronate), intramedullary rodding, physical therapy
• Differential: Can be mistaken for child abuse

What oral findings occur in Osteogenesis imperfecta?

• Dentin: Dentinogenesis imperfecta (more common in types III and IV); primary teeth more severely affected
• Wear and pulp: Rapid attrition, enamel chipping, periapical radiolucencies without caries
• Occlusion and eruption: Class III malocclusion, open bite, impacted or delayed second molars

For Osteogenesis imperfecta, how can it be confused with abuse?

• Multiple healing-stage fractures occur in both
• OI clues: blue sclerae, Wormian bones, DI, hearing loss, family history
• OI does not exclude abuse; refer appropriately

A 3-year-old has amber-gray translucent primary teeth that are wearing rapidly, and blue sclerae. What is the dental diagnosis and associated condition?

• Diagnosis: Dentinogenesis imperfecta with osteogenesis imperfecta (type I collagen, COL1A1 or COL1A2).
• Radiographs: Radiographs show bulbous crowns, cervical constriction, short roots and obliterated pulps.

What should you consider before extracting a tooth in a child with osteogenesis imperfecta who receives pamidronate?

• Assess and coordinate: confirm the reason for extraction, restorability, fracture risk, and antiresorptive history, then coordinate with the treating physician and an experienced dental surgeon as needed.
• Explain uncertainty: pediatric medication-related osteonecrosis is uncommon, but evidence is limited and the child's exposure and comorbidities matter.
• Technique and review: use gentle technique and jaw support, discuss healing risks, and arrange postoperative review.
• Retention versus extraction: a sound tooth-preserving option may be preferable; an infected nonrestorable tooth still needs definitive treatment.
• Medication limit: do not invent a bisphosphonate “drug holiday” or assume that stopping treatment eliminates risk.

Sources

• Supplemental OI dental care: Osteogenesis Imperfecta Foundation: Dental Care
• AAPD dental guidance: AAPD: Protective stabilization
• Supplemental systemic features: MedlinePlus Genetics: osteogenesis imperfecta
• Supplemental study guide: Pediatric Dental Study Guide: Osteogenesis imperfecta
• Pediatric Restorative Dentistry
• Oral and Dental Aspects of Child Abuse and Neglect